UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer: A Review

JAMA : the journal of the American Medical Association, 2019-08, Vol.322 (8), p.764

2019

Volltextzugriff (PDF)

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors

Journal of clinical oncology, 2022-08, Vol.40 (23), p.2609-2611

2022

Volltextzugriff (PDF)

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

PloS one, 2017-08, Vol.12 (8), p.e0182665-e0182665

2017

Volltextzugriff (PDF)

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non-Small Cell Lung Cancer

Clinical cancer research, 2018-01, Vol.24 (2), p.334-340

2018

Volltextzugriff (PDF)

Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer

Cell reports (Cambridge), 2020-12, Vol.33 (9), p.108444-108444, Article 108444

2020

Volltextzugriff (PDF)

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Nature (London), 2021-11, Vol.599 (7886), p.679-683

2021

Volltextzugriff (PDF)

Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Hematology/oncology clinics of North America, 2017-02, Vol.31 (1), p.101-111

2017

Volltextzugriff (PDF)

Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer

Cancer, 2018-06, Vol.124 (11), p.2272-2275

2018

Volltextzugriff (PDF)

Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade

Cancer discovery, 2021-01, Vol.11 (1), p.59-67

2021

Volltextzugriff (PDF)

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Cancer research (Chicago, Ill.), 2022-11, Vol.82 (21), p.4058-4078

2022

Volltextzugriff (PDF)

Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases

Cancer, 2018-01, Vol.124 (1), p.105-109

2018

Volltextzugriff (PDF)

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy

Current Oncology Reports, 2017-04, Vol.19 (4), p.24-24, Article 24

2017

Volltextzugriff (PDF)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2023-11, Vol.28 (11), p.978-985

2023

Volltextzugriff (PDF)

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C -Mutant Non-Small Cell Lung Cancer

JCO precision oncology, 2023-06, Vol.7 (7), p.e2300030

2023

Volltextzugriff (PDF)

KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

Clinical cancer research, 2021-05, Vol.27 (9), p.2604-2612

2021

Volltextzugriff (PDF)

The activity, safety, and evolving role of brigatinib in patients with ALK -rearranged non-small cell lung cancers

OncoTargets and therapy, 2017-01, Vol.10, p.1983-1992

2017

Volltextzugriff (PDF)

Acquired Resistance to KRAS G12C Inhibition in Cancer

The New England journal of medicine, 2021-06, Vol.384 (25), p.2382-2393

2021

Volltextzugriff (PDF)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

JTO clinical and research reports, 2022-01, Vol.3 (1), p.100256-100256, Article 100256

2022

Volltextzugriff (PDF)

Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas

JCO precision oncology, 2019 (3), p.1-9

2019

Volltextzugriff (PDF)

Trial in progress: A phase 2 study of sotorasib as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) whose tumors harbor a KRAS p.G12C mutation (CodeBreaK 201)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9150-TPS9150

2022

Volltextzugriff (PDF)

1 – 25 von 82

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(61)

Publikationsform

Sprache

Englisch
(82)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(31)
Oncology
(24)
Humans
(21)
Mutation
(15)
Lung Cancer
(12)
Lung Neoplasms - Genetics
(10)
Cancer
(9)
Lung Neoplasms - Drug Therapy
(8)
Patients
(8)
Proto-Oncogene Proteins P21 - Genetics
(8)
Carcinoma, Non-Small-Cell Lung - Genetics
(7)
Female
(7)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)
Male
(6)
Cancer Therapies
(5)
K-Ras Protein
(5)
Nsclc
(5)
Survival
(5)
Tumors
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer: A Review

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non-Small Cell Lung Cancer

Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC

Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer

Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade

The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C -Mutant Non-Small Cell Lung Cancer

KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

The activity, safety, and evolving role of brigatinib in patients with ALK -rearranged non-small cell lung cancers

Acquired Resistance to KRAS G12C Inhibition in Cancer

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas

Trial in progress: A phase 2 study of sotorasib as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) whose tumors harbor a KRAS p.G12C mutation (CodeBreaK 201)

Aktive Filter

Suchergebnisse filtern